LivaNova (NASDAQ:LIVN) Rating Lowered to Hold at StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Wednesday.

A number of other equities analysts have also recently issued reports on the company. Barclays increased their price target on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Mizuho reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, March 20th. Finally, Robert W. Baird increased their target price on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $64.40.

LivaNova Stock Performance

Shares of LIVN stock opened at $52.76 on Wednesday. The stock has a market capitalization of $2.85 billion, a PE ratio of 164.88 and a beta of 0.89. LivaNova has a one year low of $42.75 and a one year high of $59.86. The business’s 50 day simple moving average is $53.55 and its 200 day simple moving average is $50.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The firm had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.81 EPS. As a group, research analysts forecast that LivaNova will post 3.01 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the stock. Lazard Asset Management LLC purchased a new stake in LivaNova in the 2nd quarter valued at $46,000. Headlands Technologies LLC purchased a new stake in LivaNova in the 3rd quarter valued at $72,000. Point72 Middle East FZE purchased a new stake in LivaNova in the 4th quarter valued at $72,000. Picton Mahoney Asset Management purchased a new stake in LivaNova in the 3rd quarter valued at $91,000. Finally, PNC Financial Services Group Inc. raised its position in LivaNova by 16.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,853 shares of the company’s stock valued at $147,000 after buying an additional 408 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.